0.01
-0.0068(-33.50%)
Currency In USD
Address
3201 Carnegie Avenue
Cleveland, OH 44115-2634
United States of America
Phone
216 431 9900
Website
Sector
Healthcare
Industry
Biotechnology
Employees
24
First IPO Date
June 12, 2007
| Name | Title | Pay | Year Born |
| Ms. Maia A. Hansen M.B.A., M.S. | Chief Operating Officer | 962,570 | 1969 |
| Ms. Z. Kasey Rosado | Interim Chief Financial Officer | 1.51M | 1974 |
| Ms. Alison O'Sullivan M.B.A. | Vice President of HR | 0 | N/A |
| Mr. Rakesh Ramachandran MS | Head of Information Technology & Communications and Vice President | 0 | N/A |
| Dr. Robert Mays Ph.D. | Executive Vice President, Head of Regenerative Medicine & Neuroscience Programs | 0 | N/A |
| Senthil Ranganathan Ph.D. | Vice President of Technical Operations | 0 | N/A |
| Mr. James Glover B.S., P.M.P. | Executive Vice President & Head of Manufacturing | 0 | N/A |
| Mr. David Russ M.B.A. | Vice President of Supply Chain, Finance & Administration | 0 | N/A |
| Dr. Sarah Busch Ph.D. | Vice President of Regenerative Medicine & Head of Business Development | 0 | N/A |
| Ms. Ellen Gurley | Manager of Corporate Communications and Investor Relations | 0 | N/A |
| Dr. Manal Morsy M.B.A., M.D., PH.D. | Executive Vice President & Head of Global Regulatory Affairs | 0 | N/A |
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.